https://www.selleckchem.com/pr....oducts/bms-986365.ht
8 months after transplantation (HR 1.55, P = 0.042), and this adverse effect was not detected any more after 10.8 months (HR 0.58, P = 0.107). Compared with early-EBVneg group after adjusting by aGVHD and CMV viremia, HR for death from transplant-related mortality was 2.78-fold higher in patients with early-EBV viremia in piecewise constant Cox analysis (P = 0.006), and this adverse effect was not detected any more after the cut-point time (HR 0.67, P = 0.361). No differences in terms of relapse and relapse mortality were observed be
Like
Comment
Share
